Article

Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern

2022-07-18

Abstract excerpt

In this South African phase 1/2b study, we demonstrated vaccine efficacy (VE) of two doses of AZD1222 for asymptomatic and symptomatic SARS-CoV-2 infection: 90.6% against wild-type and 77.1% against the Delta variant ≥9 months after vaccination. VE against infection with the Beta variant, which preceded circulation of Delta, was 6.7%. <h4>Clinical trial identifier</h4> CT.gov NCT04444674

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: df18c28c-3e08-51b3-8120-c09dc705f8fa
DOI: 10.1101/2022.07.18.22277743

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of ConcernDOI 10.1101/2022.07.18.22277743Read

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in BrazilSemantic proximity Read

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trialSemantic proximity Read

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)Semantic proximity Read

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV InfectionSemantic proximity Read

Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South AfricaSemantic proximity Read

Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a TrialSemantic proximity Read

Expert Review of Global Real-World Vaccine Effectiveness Against SARS-CoV-2Semantic proximity Read

A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccinesSemantic proximity Read

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.Semantic proximity Read

Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysisSemantic proximity Read

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and diseaseSemantic proximity Read

Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care settingSemantic proximity Read